Literature DB >> 7528018

Increased expression of endothelial constitutive nitric oxide synthase in rat aorta during pregnancy.

R M Goetz1, I Morano, T Calovini, R Studer, J Holtz.   

Abstract

The mechanisms underlying enhanced vascular reactivity in pregnancy are not yet defined. In this study we have investigated the potential role of endothelium-derived vasodilator nitric oxide (EDNO). EDNO-mediated dilatory responses in vitro were markedly increased in aorta of pregnant as compared with nonpregnant rats. This increase in EDNO-releasability was accompanied by a two-fold increase in mRNA of endothelial constitutive nitric oxide synthase (NOS-III). Chronically substituted estrogen, but neither progesterone nor testosterone induced an upregulation of NOS-III mRNA in aorta of gonadectomized rats which amounted to about half that induced in aorta of pregnant rats. Thus, increased EDNO-releasability and increased NOS-III mRNA contribute to enhanced vascular reactivity in pregnancy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7528018     DOI: 10.1006/bbrc.1994.2750

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  19 in total

1.  Evidence for a familial pregnancy-induced hypertension locus in the eNOS-gene region.

Authors:  R Arngrímsson; C Hayward; S Nadaud; A Baldursdóttir; J J Walker; W A Liston; R I Bjarnadóttir; D J Brock; R T Geirsson; J M Connor; F Soubrier
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

2.  Sex- and isoform-specific mechanism of neuroprotection by transgenic expression of P450 epoxygenase in vascular endothelium.

Authors:  Jia Jia; Catherine M Davis; Wenri Zhang; Matthew L Edin; Sari Jouihan; Taiping Jia; J Alyce Bradbury; Joan P Graves; Laura M DeGraff; Craig R Lee; Oline Ronnekleiv; Ruikang Wang; Yun Xu; Darryl C Zeldin; Nabil J Alkayed
Journal:  Exp Neurol       Date:  2016-02-20       Impact factor: 5.330

Review 3.  Preeclampsia beyond pregnancy: long-term consequences for mother and child.

Authors:  Hannah R Turbeville; Jennifer M Sasser
Journal:  Am J Physiol Renal Physiol       Date:  2020-04-06

4.  Increased expression and activity of heme oxygenase-2 in pregnant rat aorta is not involved in attenuated vasopressin-induced contraction.

Authors:  Maram G Katoue; Islam Khan; Mabayoje A Oriowo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-11-05       Impact factor: 3.000

5.  Nitric oxide synthase in human placenta and umbilical cord from normal, intrauterine growth-retarded and pre-eclamptic pregnancies.

Authors:  R A Rutherford; A McCarthy; M H Sullivan; M G Elder; J M Polak; J Wharton
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

Review 6.  Nitric oxide and cardiovascular disease.

Authors:  M McIntyre; A F Dominiczak
Journal:  Postgrad Med J       Date:  1997-10       Impact factor: 2.401

7.  Lack of beneficial effects on the NO-donor, molsidomine, in the L-NAME-induced pre-eclamptic syndrome in pregnant rats.

Authors:  C Richer; H Boulanger; S Es-Slami; J F Giudicelli
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

8.  Adaptive regulation of endothelin receptor type-A and type-B in vascular smooth muscle cells during pregnancy in rats.

Authors:  Minghui Ou; Yiping Dang; Marc Q Mazzuca; Rebecca Basile; Raouf A Khalil
Journal:  J Cell Physiol       Date:  2014-04       Impact factor: 6.384

9.  The vasoconstrictor effects of L-NAME, a nitric oxide synthase inhibitor, in pregnant rabbits.

Authors:  G Losonczy; I Mucha; V Müller; T Kriston; Z Ungvári; L Tornóci; L Rosivall; R Venuto
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

10.  Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production.

Authors:  J F Arnal; S Clamens; C Pechet; A Negre-Salvayre; C Allera; J P Girolami; R Salvayre; F Bayard
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.